**Question:** Beta blocker that can be used in renal failure is all except-

A. Labetalol
B. Carvedilol
C. Atenolol
D. Metoprolol

**Core Concept:** Beta blockers are a class of medications that primarily target beta receptors in the cardiovascular system, which can have effects on blood pressure, heart rate, and myocardial contractility. In patients with renal failure, some beta blockers may accumulate due to decreased renal clearance, leading to potential adverse effects.

**Why the Correct Answer is Right:** Labetalol, Carvedilol, and Atenolol are selective beta-1 blockers, meaning they primarily target beta-1 receptors. In renal failure, their accumulation can lead to worsening of hypertension and heart failure due to decreased renal clearance.

**Why Each Wrong Option is Incorrect:**

A. **Labetalol:** Labetalol is a mixed beta-1 and beta-2 blocker, which means it has equal affinity for beta-1 and beta-2 receptors. In contrast to selective beta-1 blockers, labetalol does not worsen hypertension or heart failure in renal failure patients, making it the correct choice in this context.

B. **Carvedilol:** Similar to Labetalol, Carvedilol is a mixed beta-1 and beta-2 blocker, which makes it unsuitable for renal failure patients due to potential worsening of hypertension and heart failure.

C. **Atenolol:** Atenolol is a selective beta-1 blocker, which can lead to worsening of hypertension and heart failure in renal failure patients.

D. **Metoprolol:** Metoprolol is also a selective beta-1 blocker, which can lead to worsening of hypertension and heart failure in renal failure patients.

**Clinical Pearl:**

In patients with renal failure, it is essential to choose beta-blockers with a lower risk of worsening hypertension and heart failure, such as labetalol or carvedilol. These medications have a balanced affinity for beta-1 and beta-2 receptors, allowing for a more appropriate management of hypertension and heart failure in these patients. Selective beta-1 blockers like atenolol and metoprolol should be avoided in renal failure due to the potential for worsening of hypertension and heart failure.